3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Smoking Cessation
7
Carcinoma, Non-Small-Cell Lung
4
Tobacco Use Disorder
3
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Small Cell Lung Carcinoma
2
Neoplasms
2
Vaping
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Tobacco Use
1
Tobacco Smoking
1
Substance-Related Disorders
1
Stomach Neoplasms
1
Smoking
1
Recurrence
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Trastuzumab
597
Paclitaxel
562
Cyclophosphamide
545
Docetaxel
479
Capecitabine
388
Letrozole
350
Fulvestrant
311
Doxorubicin
285
Carboplatin
277
Tamoxifen
257
Anastrozole
219
exemestane
211
Epirubicin
210
Radiotherapy
197
Bevacizumab
189
pertuzumab
177
Gemcitabine
163
Vinorelbine
162
pembrolizumab
161
Lapatinib
161
palbociclib
152
Exercise
132
Fluorouracil
118
Albumin-Bound Paclitaxel
116
eribulin
108
Magnetic Resonance Spectroscopy
108
130-nm albumin-bound paclitaxel
107
Everolimus
103
Taxes
96
Cisplatin
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Breast Neoplasms
×
Nicotine Replacement Therapy
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled